Iuliana Dărășteanu *
* Iuliana Dărășteanu, medic rezident anul V, doctorand, boli infecțioase, Institutul de Boli lnfecțioase Prof. dr. Matei Balș”, București
Abstract
Lipodystrophy due to antiretrovirales
Both hyperlipidemia and elevated serum glucose concentrations have been recognized in patients receiving protease inhibitor therapy. Abnormalities in fat distribution, including enlargement of the dorsocervical fat pad, increased abdominal fat, and, in women, breast enlargement, have been described as lipodystrophy syndrome. The obseFVed changes in the serum lipid concentrations occurred as early as 8 weeks after initiation of therapy and generally increased over time. Abnormalitis in lipid metabolism were also noted in association with HIV infection before the use of protease inhibitors. The mechanisms whereby serum lipid levels are increased in patients receving treatment with protease inhibitors remain unclear. It is possible that different aspects of the syndrome have different causes. Limited data suggest that for some patients, therapy switches may have a positive effect on metabolic or morphologic changes.